In PepBank now:147 peptides, 6 blends and 13 other compounds97,577 study results from 17,383 studies8,473 clinical trialsUpdated
Comparing 2 peptides · Data version 308560
Swipe sideways to see every peptide.
| Peptide | Synthetic analog Setmelanotide | Synthetic analog Liraglutide | |
|---|---|---|---|
| Identity | |||
| Kind | Synthetic analog | Synthetic analog | |
| Area | Weight and metabolic | Weight and metabolic | |
| Evidence | |||
| Amount of evidence | 332 | 4,766 | |
| Evidence level | Has results from studies in people | Has results from studies in people | |
| Safety | |||
| Safety results | 91 (91 in people) | 805 (793 in people) | |
| Status | |||
| Approval | |||
| Sport (WADA) | |||
| Registered trials | 25 · 5 active1 more mentions it but does not test it | 469 · 30 active49 more mention it but do not test it | |
Shared outcomes
From the regulatory data of each peptide.
The FDA label for Imcivree says: “Reduce excess body weight and maintain weight reduction long term”
Outcome groups with study results for at least two of these peptides. Counts include only results from studies that gave the peptide. Bar length is the number of results, on one scale. The bars show how much was studied, not how large an effect was. A peptide with more studies can look stronger here without being stronger. For results, see the randomized results above.
| Outcome group | Setmelanotide | Liraglutide |
|---|---|---|
| Glycemic controlMetabolic and weight | 761 | 1,1171067491 |
PepBank is a research reference. Talk to a doctor before you use any peptide.
The EMA label for Victoza says: “Adults, adolescents and children 10 years and older with insufficiently controlled type 2 diabetes, as an adjunct to diet and exercise”
| Body weightMetabolic and weight | 907812 | 83481717 |
|---|
| Adverse eventsWhole body | 5656 | 50449311 |
|---|
| Gastrointestinal adverse eventsGastrointestinal | 1111 | 185185 |
|---|
| LipidsMetabolic and weight | 871 | 14313733 |
|---|
| Liver fat and liver functionLiver | 77 | 1361279 |
|---|
| Appetite and food intakeMetabolic and weight | 35278 | 1129517 |
|---|
| Inflammation markersImmune and inflammation | 11 | 117100152 |
|---|
| Kidney functionKidney and urinary | 33 | 1049932 |
|---|
| PharmacokineticsPharmacology | 211 | 969231 |
|---|
| Receptor activity and mechanismPharmacology | 17512 | 8250626 |
|---|
| Quality of lifeWhole body | 2323 | 3333 |
|---|
Each analog against its native parent, residue by residue. Substitutions, non-standard residues and modifications are marked. Calculated from the two sequences.
Setmelanotide differs from Alpha-melanocyte-stimulating hormone at 5 positions.
What is different
Liraglutide differs from Glucagon-like peptide 1 (7-37) at 1 position and carries 1 added group.
What is different
Registered trials, ranked by phase (late phases first), then posted results and enrollment. Status is the registry status. Study results come from published studies. Results posted at ClinicalTrials.gov are shown on each trial page.
Top 3 of 25 trials, ranked by phase, then posted results and enrollment: 1 ongoing · 2 completed · 3 with posted results · source ClinicalTrials.gov (opens in a new tab)
Rhythm Pharmaceuticals, Inc.205 participants15 Jul 2018 to 9 Jan 2025
Obesity Associated With Defects in Leptin-melanocortin Pathway
Rhythm Pharmaceuticals, Inc.143 participants26 Apr 2023 to est. 16 Apr 2027
Hypothalamic Obesity
Rhythm Pharmaceuticals, Inc.77 participants5 Aug 2021 to 7 Apr 2022
Healthy
1 more mentions it but does not test it. They only measure it or name it in their text.
Top 3 of 469 trials, ranked by phase, then posted results and enrollment: 3 completed · 3 with posted results · source ClinicalTrials.gov (opens in a new tab)
Novo Nordisk A/S9,341 participants31 Aug 2010 to 17 Dec 2015
Diabetes · Diabetes Mellitus, Type 2
GRADE Study Group7,850 participantsMay 2013 to 30 Apr 2021
Type 2 Diabetes · Comparative Effectiveness of Glycemia-lowering Medications
Novo Nordisk A/S3,731 participants1 Jun 2011 to 2 Mar 2015
Metabolism and Nutrition Disorder · Obesity
For each outcome that two or more peptides have results for: the best result of a single randomized trial, on the same measure (the same kind of number, the same unit). When a trial has several dose arms, the cell shows the highest dose arm. The trials differ in people, length and dose, so a gap between two cells is not proof that one peptide works better.
| Outcome | Setmelanotide | Liraglutide |
|---|---|---|
| Body weightMetabolic and weightCompared as: value in the arm that got the peptide, in % | −16.5% BMI change Placebo: 3.3% Dose studied: 1.5 to 3.0 mg once daily52 weeks after dose escalationn = 1202026 |
49 more mention it but do not test it. They only measure it or name it in their text.
−5.8% BMI change Placebo: 1.6% Dose studied: 3.0 mg or maximum tolerated dose once daily56 weeksn = 822025 |
| Adverse eventsGastrointestinalCompared as: share of people in the arm that got the peptide, in % | 100% Participants with adverse events Placebo group: 90% Dose studied: 1.5 to 3.0 mg once daily52 weeks after dose escalationn = 1202026 | 56.3% Participants with adverse events Placebo: 62.5% Dose studied: 0.3 mg start, weekly escalation up to 3.0 mg or maximum tolerated dosen = 242019 |
|---|
−16.5%
BMI change
Placebo: 3.3%
Dose studied: 1.5 to 3.0 mg once daily52 weeks after dose escalationn = 1202026
−5.8%
BMI change
Placebo: 1.6%
Dose studied: 3.0 mg or maximum tolerated dose once daily56 weeksn = 822025
100%
Participants with adverse events
Placebo group: 90%
Dose studied: 1.5 to 3.0 mg once daily52 weeks after dose escalationn = 1202026
56.3%
Participants with adverse events
Placebo: 62.5%
Dose studied: 0.3 mg start, weekly escalation up to 3.0 mg or maximum tolerated dosen = 242019
The other peptides have no randomized result on the same measure, so these results cannot be set side by side.
| Outcome | Setmelanotide | Liraglutide |
|---|---|---|
| Appetite and food intakeMetabolic and weightCompared as: difference from placebo, in meals/day | No comparable result 1 randomized-trial result measure it in another way or another unit. | −1 meals/day Meal replacements per day difference Dose studied: 1.2 mg per dayn = 522015 |
| Quality of lifeWhole bodyCompared as: difference from placebo, in points | No randomized trial result 23 results from other study designs. | 3.4 points IWQOL-Lite estimated treatment difference Dose studied: 3.0 mg3 yearsn = 2,2102018 |
| SleepSleepCompared as: difference from placebo, in events h(-1) | No randomized trial result 1 result from other study designs. | −6.1 events h(-1) Estimated treatment difference Dose studied: 3.0 mg32 weeksn = 3592016 |
| Glycemic controlMetabolic and weightCompared as: difference from placebo, in % | No randomized trial result 7 results from other study designs. | −1.09% HbA1c difference Dose studied: 1.8 mg once daily26 weeksn = 3442009 |
| Treatment adherence and retentionPharmacologyCompared as: value in the arm that got the peptide, in % | No randomized trial result 1 result from other study designs. | 65% Trial completion Placebo: 53.4% Dose studied: 3.0 mg/d56 weeksn = 1322025 |
| Body compositionMetabolic and weightCompared as: difference from placebo, in % | No randomized trial result 2 results from other study designs. | −0.24% Treatment difference Dose studied: 3.0 mg target dose, once daily40 weeksn = 1282024 |
| Inflammation markersImmune and inflammationCompared as: difference from placebo, in ng/ml | No randomized trial result 1 result from other study designs. | 14.9 ng/ml Serum NGAL difference Dose studied: 3 mg/d52 weeksn = 1272025 |
| LipidsCardiovascularCompared as: difference from placebo, in lipids | No randomized trial result 8 results from other study designs. | 21 lipids Lipids decreased 26 weeksn = 1022021 |
| Respiratory functionRespiratoryCompared as: difference from placebo, in % of predicted | No randomized trial result 6 results from other study designs. | 5.2 % of predicted ΔFVC Dose studied: 1.8 mg daily7 weeksn = 762022 |
| Liver fat and liver functionLiverCompared as: difference from placebo, in % | No randomized trial result 7 results from other study designs. | −44% Liver fat reduction · Shown as a change. The study reports a liver fat reduction of this size. Dose studied: 1.8 mg/d26 weeksn = 722018 |
No comparable result
1 randomized-trial result measure it in another way or another unit.
−1 meals/day
Meal replacements per day difference
Dose studied: 1.2 mg per dayn = 522015
No randomized trial result
23 results from other study designs.
3.4 points
IWQOL-Lite estimated treatment difference
Dose studied: 3.0 mg3 yearsn = 2,2102018
No randomized trial result
1 result from other study designs.
−6.1 events h(-1)
Estimated treatment difference
Dose studied: 3.0 mg32 weeksn = 3592016
No randomized trial result
7 results from other study designs.
−1.09%
HbA1c difference
Dose studied: 1.8 mg once daily26 weeksn = 3442009
No randomized trial result
1 result from other study designs.
65%
Trial completion
Placebo: 53.4%
Dose studied: 3.0 mg/d56 weeksn = 1322025
No randomized trial result
2 results from other study designs.
−0.24%
Treatment difference
Dose studied: 3.0 mg target dose, once daily40 weeksn = 1282024
No randomized trial result
1 result from other study designs.
14.9 ng/ml
Serum NGAL difference
Dose studied: 3 mg/d52 weeksn = 1272025
No randomized trial result
8 results from other study designs.
21 lipids
Lipids decreased
26 weeksn = 1022021
No randomized trial result
6 results from other study designs.
5.2 % of predicted
ΔFVC
Dose studied: 1.8 mg daily7 weeksn = 762022
No randomized trial result
7 results from other study designs.
−44%
Liver fat reduction · Shown as a change. The study reports a liver fat reduction of this size.
Dose studied: 1.8 mg/d26 weeksn = 722018